Clinical Trial

IGHID 12334 - After the Flood: Optimal Strategies to Prevent Malaria Epidemics Caused by Severe Flooding

Study acronym: IGHID12334
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to test different ways to prevent malaria infections after flooding. To accomplish this, the investigators will assign villages to different control strategies and measure the number of malaria infections in each of the villages. Residents of all villages will receive new bed nets, but in some villages, residents will be provided with a monthly medication Dihydroartemisinin-piperaquine (DP) (a drug that is approved by the World Health Organization (WHO) and regulatory authorities and widely used in Africa for Malaria treatment. This drug is not approved by Food and Drug Administration (FDA) because it is not used in the US,) to prevent malaria, while others will also receive a treatment that can be placed into pools of water around the home to prevent mosquitoes from breeding there. The investigators will monitor the participant and their household members for mosquitoes and malaria over a period of 12 months after the flooding This study is important because, similar approaches could be used to prevent malaria after floods, which is occurring more frequently.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-10; most recent amendment 2025-08-06.
Status change: Recruiting → Active, Not Recruiting 2025-08-06
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06870344
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), North Carolina State University, Mbarara University of Science and Technology
Conditions Malaria Infection, Malaria Falciparum
Enrollment 36,000 participants
Start Date 2025-03-12
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-08